This report analyzes key aspects of initial public offerings (IPOs) for technology and life sciences companies that went public in the first half of 2016. Our IPO Survey was developed for clients, friends and others interested in considering the data surrounding recent IPO activity. Downloading the full report will provide you access to a number of tables and charts that offer a graphical view of key parameters as well as a sense of recent trends.
- Overall IPO activity for technology and life sciences companies declined in the first and second quarters of 2016, with the number of deals down sequentially compared to the third and fourth quarters of 2015.
- While life sciences IPOs fell to their lowest half-year rate since 2011, their totals far outpaced technology IPOs. Life sciences companies completed 16 deals in the first half of 2016 compared to four completed by technology companies in the same period.
- There were no large blockbuster deals completed in the first half of the year, with deal sizes generally ranging from $35 to $250 million.
- Pricing was a challenge for life sciences IPOs in the first half, as a majority of the deals priced below the red herring range.
- Participation by insiders continues to be an important feature of life sciences IPOs, where most deals had substantial insider participation.